438 related articles for article (PubMed ID: 12064791)
1. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
Murphy MD; Rosen HR; Marousek GI; Chou S
Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
[TBL] [Abstract][Full Text] [Related]
2. Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b.
Saito T; Ito T; Ishiko H; Yonaha M; Morikawa K; Miyokawa A; Mitamura K
Am J Gastroenterol; 2003 Jun; 98(6):1377-83. PubMed ID: 12818284
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
[TBL] [Abstract][Full Text] [Related]
4. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
Yang SS; Lai MY; Chen DS; Chen GH; Kao JH
Liver Int; 2003 Dec; 23(6):426-33. PubMed ID: 14986817
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment.
Yahoo N; Sabahi F; Shahzamani K; Malboobi MA; Jabbari H; Sharifi H; Mousavi-Fard SH; Merat S
J Med Virol; 2011 Aug; 83(8):1332-7. PubMed ID: 21678437
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
[TBL] [Abstract][Full Text] [Related]
8. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.
Muñoz de Rueda P; Casado J; Patón R; Quintero D; Palacios A; Gila A; Quiles R; León J; Ruiz-Extremera A; Salmerón J
J Virol; 2008 Jul; 82(13):6644-53. PubMed ID: 18448540
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
[TBL] [Abstract][Full Text] [Related]
10. Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness.
Yokozaki S; Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
J Med Virol; 2011 Oct; 83(10):1727-32. PubMed ID: 21837788
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment.
Berg T; Mas Marques A; Höhne M; Wiedenmann B; Hopf U; Schreier E
Hepatology; 2000 Dec; 32(6):1386-95. PubMed ID: 11093746
[TBL] [Abstract][Full Text] [Related]
12. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.
Sarrazin C; Bruckner M; Herrmann E; Rüster B; Bruch K; Roth WK; Zeuzem S
Virology; 2001 Oct; 289(1):150-63. PubMed ID: 11601926
[TBL] [Abstract][Full Text] [Related]
13. Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy.
Chayama K; Suzuki F; Tsubota A; Kobayashi M; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Takahashi N; Kinoshita M; Kumada H
Hepatology; 2000 Nov; 32(5):1138-44. PubMed ID: 11050067
[TBL] [Abstract][Full Text] [Related]
14. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
[TBL] [Abstract][Full Text] [Related]
15. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?
Macquillan GC; Niu X; Speers D; English S; Garas G; Harnett GB; Reed WD; Allan JE; Jeffrey GP
J Gastroenterol Hepatol; 2004 May; 19(5):551-7. PubMed ID: 15086599
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
Mori N; Imamura M; Kawakami Y; Saneto H; Kawaoka T; Takaki S; Aikata H; Takahashi S; Chayama K;
J Med Virol; 2009 Apr; 81(4):640-9. PubMed ID: 19235866
[TBL] [Abstract][Full Text] [Related]
17. Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load.
Ukai K; Ishigami M; Yoshioka K; Kawabe N; Katano Y; Hayashi K; Honda T; Yano M; Goto H
World J Gastroenterol; 2006 Jun; 12(23):3722-8. PubMed ID: 16773689
[TBL] [Abstract][Full Text] [Related]
18. The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India.
Goyal A; Hofmann WP; Hermann E; Traver S; Hissar SS; Arora N; Blum HE; Zeuzem S; Sarrazin C; Sarin SK
Med Microbiol Immunol; 2007 Mar; 196(1):11-21. PubMed ID: 16955308
[TBL] [Abstract][Full Text] [Related]
19. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
[TBL] [Abstract][Full Text] [Related]
20. Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.
Gerotto M; Sullivan DG; Polyak SJ; Chemello L; Cavalletto L; Pontisso P; Alberti A; Gretch DR
J Virol; 1999 Sep; 73(9):7241-7. PubMed ID: 10438811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
